- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05168644
Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects
Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of Inhaled Niclosamide in Healthy Adult Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1, randomized, 2 part double-blind, placebo-controlled trial to evaluate the safety and PK profiles of Niclosamide Inhalation Powder in a SAD/MAD study design.
Part A is a double-blinded, placebo-controlled, randomized, dose- ranging single dose study evaluating four different dose levels.
On Day 1 of each group, two selected subjects (sentinel subjects) will receive either Niclosamide Inhalation Powder or a matching placebo. Blood samples and safety measurements including Adverse Events (AEs) will be collected over 24 hour period following the drug administration. The safety results to be evaluated include AEs, concomitant medications, out of specification clinical laboratory results, vital signs, Electrocardiograms (ECGs), visual examinations, pulmonary function tests, pulse oximetry results and any new findings on physical examinations. If the administration is safe as deemed by Principal Investigator & Medical Monitor, the remaining six subjects will be dosed (5 dosed with Niclosamide Inhalation Powder and 1 dosed with matching placebo), with identical safety and PK procedures performed after minimum of 2 days interval. A minimum of 3 days will separate each dose escalation, with the remaining dose groups dosed in a sentinel fashion.
Part B is a double-blinded, placebo-controlled, randomized, dose- ranging multi-dose study evaluating two different dose levels. Dose level 1 of Part B can begin once the data monitoring committee reviews the safety data and indicates safety is present. Niclosamide Inhalation Powder will be administered twice daily (BID) × 9 doses. Blood samples for safety and PK will be collected throughout confinement, which is 7 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Mount Royal, Quebec, Canada
- Altasciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Agree to use acceptable contraception or is not able to bear children.
- Body mass index (BMI) within ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2 at Screening (body weight of at least 50.0 kg and no more than120 kg at Screening).
- Non-smoker or ex-smoker (stopped using nicotine products for at least 12 months prior to the first study drug administration and throughout the study).
- Have no clinically significant diseases, including asthma, captured in the medical history or on the physical examination, visual examination, clinical laboratory assessments, and/or ECG.
- A forced expiratory volume during the first second (FEV1) ≥ 80% at Screening and Check-in.
Exclusion Criteria
- Female who is lactating, is pregnant or planning to become pregnant according to the pregnancy test at Screening or prior to the first study drug administration.
- Is mentally or legally incapacitated or unable to provide informed consent.
- History or presence of alcoholism or drug abuse within the past 2 years prior to the first study drug administration.
- History or presence of hypersensitivity or idiosyncratic reaction to niclosamide or any portion of the placebo.
- Has had surgery or any medical condition within 6 months prior to first study drug administration which may affect the absorption, distribution, metabolism, or elimination of the study drug, in the opinion of the PI or designee.
- Use of albuterol or a similar bronchodilator.
- Immunization with a COVID-19 vaccine in the 14 days prior to the first study drug administration.
- Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason.
- History or allergy of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Unable to refrain from or anticipates the use of:
- Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study.
- Seasonal use of albuterol or other similar inhalers throughout study participation, beginning 14 days prior to the first dosing or 5 half-lives, whichever is longer.
- Use of St. John's wort in the 28 days prior to the first study drug administration.
- Positive Screening results for tuberculosis, HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus tests, or a positive test for alcohol, cotinine, and/or drugs of abuse.
- Participation in another clinical study within 30 days prior to the first study drug administration. The 30-day window will be derived from the date of the last study drug administration.
- Had a treatment with another investigational drug within 5 times the elimination half-life, if known (eg, a marketed product) or within 30 days (if the elimination half-life is unknown) prior to the first study drug administration.
- Donation of plasma in the 14 days prior to the first study drug administration.
- Donation or loss of 500 mL or more of blood in the 56 days prior to the first study drug administration.
- Demonstrates an inability to operate the inhalation device after training.
- History or presence of any drug or food allergies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Drug: Niclosamide Inhalation Powder
PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg. PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID. |
Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder.
The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
|
PLACEBO_COMPARATOR: Drug: Placebo
PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. SAD subjects (Part A) will receive a single dose of Placebo. PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses. |
Placebo will be supplied as capsules, each capsule will contain no active ingredient.
The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who experience Adverse Events (AEs), Serious Adverse Events (SAEs) and withdrawals due to AEs
Time Frame: Baseline through study completion, up to 43 days
|
Number of AEs, SAEs, and discontinuation due to AEs
|
Baseline through study completion, up to 43 days
|
Number of participants who experience vital sign abnormalities
Time Frame: Baseline through study completion, up to 43 days
|
Number of participants with potentially clinically significant vital sign values
|
Baseline through study completion, up to 43 days
|
Number of participants who experience pulse oximetry abnormalities
Time Frame: Baseline through study completion, up to 43 days
|
Number of participants with potentially clinically significant pulse oximetry values
|
Baseline through study completion, up to 43 days
|
Mean change from baseline in forced expiratory volume (FEV1)
Time Frame: Baseline through study completion, up to 43 days
|
Spirometry used to measure FEV1 lung function
|
Baseline through study completion, up to 43 days
|
Mean change from baseline in forced vital capacity (FVC)
Time Frame: Baseline through study completion, up to 43 days
|
Spirometry used to measure FVC lung function
|
Baseline through study completion, up to 43 days
|
Mean change from baseline in FEV1/FVC ratio
Time Frame: Baseline through study completion, up to 43 days
|
Spirometry used to measure FEV1 and FVC lung function
|
Baseline through study completion, up to 43 days
|
Mean change from baseline in QTcF changes via ECG
Time Frame: Baseline through study completion, up to 43 days
|
Number of participants with potentially clinically significant ECG values
|
Baseline through study completion, up to 43 days
|
Number of participants who experience physical examination abnormalities
Time Frame: Baseline through study completion, up to 43 days
|
Number of participants with potentially clinically significant physical examination findings
|
Baseline through study completion, up to 43 days
|
Number of participants who experience laboratory test abnormalities
Time Frame: Baseline through study completion, up to 43 days
|
Number of participants with potentially clinically significant laboratory test results
|
Baseline through study completion, up to 43 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK of Niclosamide in plasma: Area under the plasma-concentration time curve (AUC)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for plasma analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Area under the concentration time curve, from time 0 to the last observed non-zero concentration (AUC0-tlast)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Maximum observed concentration (Cmax)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Trough or minimum concentration (Ctrough)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Concentration at the end of the dosing interval (Ct)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Time to maximal observed concentration (tmax)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Accumulation ratio (comparing Day 5 Cmax to Day 1 Cmax)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Accumulation ratio (comparing Day 5 AUCtau to Day 1 AUC0-12)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Area under the plasma-concentration time curve over the first 12 hours after dosing (AUC0-12)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Area under the concentration time curve from time 0 extrapolated to infinity (AUC∞)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Termination elimination half-life (t½)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Apparent total body clearance (CL/F)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
PK of Niclosamide in plasma: Apparent volume of distribution during the terminal elimination phase (Vz/F)
Time Frame: Baseline through study completion, up to 43 days
|
Blood samples will be collected for analysis
|
Baseline through study completion, up to 43 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TFF-N1-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Niclosamide Inhalation Powder
-
AlgiPharma ASImperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaboratorsWithdrawnCystic FibrosisGermany
-
AstraZenecaCompletedAsthma | Chronic Obstructive Pulmonary Disease COPDUnited States
-
Mannkind CorporationCompletedDiabetes Mellitus, Type 2 | Healthy MalesNetherlands
-
Mannkind CorporationCompletedHealthy VolunteersUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveJapan
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
-
Mannkind CorporationCompletedDiabetes Mellitus, Type 2Netherlands
-
GlaxoSmithKlineCompletedAsthmaUnited States, Germany, Japan, Romania, Russian Federation, Poland
-
Savara Inc.CompletedCystic Fibrosis | MRSAUnited States, Canada